Pharmaceutical Technology

JULY 14, 2022

Pharmaceutical Technology looks at drugs and biologics with recent regulatory verdicts that will likely impact manufacturing volumes. In this ongoing series , we put a spotlight on contracts between pharma companies and contract manufacturing organizations (CMOs).

Manufacturing 130

Manufacturing Drugs Vaccination Vaccine 130

Pharmaceutical Technology

DECEMBER 6, 2022

HPAPIs may now represent more than 30% of the drug development pipeline. Within that figure, GlobalData estimates that around 60% of pipeline HPAPIs are developed to target oncology. Manufacturing these highly potent and often cytotoxic drugs introduces many risks for operators and the environment.

Containment 130

Containment Development Drugs Contract Manufacturing 130

Pharmaceutical Technology

JUNE 14, 2023

This, coupled with small pharma companies being unable to acquire or access containment capabilities in-house, means that the demand for innovative specialized small molecule capabilities remains high. Furthermore, the number of marketed high potency APIs (HPAPIs) tends to increase over time as more HPAPIs in development gain approval.

Containment 130

Containment Manufacturing Contract Manufacturing Bioavailability 130